Clanotech granted orphan drug designation by EMA for post-glaucoma surgery drug CLT-28643

20 October 2014

Swedish ophthalmic specialist Clanotech, which is 80% owned by Karolinska Development, has received orphan drug designation from the European Medicines Agency for its anti-fibrotic and anti-angiogenic candidate drug CLT-28643.

The drug is being investigated for potential use in prevention of scarring post-glaucoma filtration surgery. The company’s lead substance, an α5β1-integrin antagonist, is expected to benefit the wound-healing process with its anti-angiogenic, anti-fibrotic and anti-inflammatory properties.

Clanotech’s receipt of orphan drug designation will significantly shorten a future market approval process and reinforce market exclusivity for the product when launched.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK